secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001641172-25-009564
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Therapeutics sells PRV for $155M cash; expects profitability early 2026
------------------------------------------------------------------------------

- Definitive agreement to sell Rare Pediatric Disease PRV for $155M in gross cash proceeds at closing.
- PRV awarded by FDA on April 28, 2025 upon approval of ZEVASKYN (prademagene zamikeracel) for RDEB.
- CFO: proceeds provide over two years of operating expenses without additional financing; ZEVASKYN launch Q3 2025.
- Expects profitability in early 2026; closing subject to HSR waiting period; Stifel and Jefferies as advisors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000164117225009564/0001641172-25-009564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000164117225009564/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-009564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer